Crexendo
Through the investors’ lenses
Each of these investors has said in public what they look at before buying. Click a name to see how this company measures up — a tick where it passes one of their tests, a cross where it does not.
Warren Buffett 1/4
| Measure | CXDO | Checked against | |
|---|---|---|---|
| Owner earnings | $-50.00k | positive | ✗ |
| Return on equity | -0.8% | median 11.7% | ✗ |
| Debt to equity | 0.02x | median 0.79x | ✓ |
| Operating margin | -3.2% | median 15.0% | ✗ |
Passes 1 of 4. To be clear: Warren Buffett has never said anything about Crexendo. These are the company’s own figures put through the tests he described. What he looks at, and why →
Terry Smith 1/3
| Measure | CXDO | Checked against | |
|---|---|---|---|
| Return on capital employed | -3.7% | median 10.1% | ✗ |
| Cash conversion | — | median 1.78x | — |
| Operating margin | -3.2% | median 15.0% | ✗ |
| Debt to equity | 0.02x | median 0.79x | ✓ |
Passes 1 of 3. To be clear: Terry Smith has never said anything about Crexendo. These are the company’s own figures put through the tests he described. What he looks at, and why →
Charlie Munger 0/3
| Measure | CXDO | Checked against | |
|---|---|---|---|
| Return on capital employed | -3.7% | median 10.1% | ✗ |
| Return on equity | -0.8% | median 11.7% | ✗ |
| Operating margin | -3.2% | median 15.0% | ✗ |
Passes 0 of 3. To be clear: Charlie Munger has never said anything about Crexendo. These are the company’s own figures put through the tests he described. What he looks at, and why →
Chuck Akre 1/3
| Measure | CXDO | Checked against | |
|---|---|---|---|
| Return on equity | -0.8% | median 11.7% | ✗ |
| Debt to equity | 0.02x | median 0.79x | ✓ |
| Cash conversion | — | median 1.78x | — |
| Return on equity, sustained | 2 of 10 | 8 of 10 above median | ✗ |
Passes 1 of 3. To be clear: Chuck Akre has never said anything about Crexendo. These are the company’s own figures put through the tests he described. What he looks at, and why →
Philip Fisher 1/4
| Measure | CXDO | Checked against | |
|---|---|---|---|
| Operating margin | -3.2% | median 15.0% | ✗ |
| Net margin | -0.7% | median 10.2% | ✗ |
| Return on capital employed | -3.7% | median 10.1% | ✗ |
| Operating margin, held or improving | 6.9% | 10-yr median -3.2% | ✓ |
Passes 1 of 4. To be clear: Philip Fisher has never said anything about Crexendo. These are the company’s own figures put through the tests he described. What he looks at, and why →
Walter Schloss 2/2
| Measure | CXDO | Checked against | |
|---|---|---|---|
| Current ratio | 1.65x | median 1.25x | ✓ |
| Debt to equity | 0.02x | median 0.79x | ✓ |
Passes 2 of 2. To be clear: Walter Schloss has never said anything about Crexendo. These are the company’s own figures put through the tests he described. What he looks at, and why →
Benjamin Graham 1/3
| Measure | CXDO | Checked against | |
|---|---|---|---|
| Current ratio | 1.65x | 2.00x published | ✗ |
| Long-term debt to working capital | 0.16x | 1.00x published | ✓ |
| Positive earnings, ten years running | 2 yrs | 10 published | ✗ |
Passes 1 of 3. To be clear: Benjamin Graham has never said anything about Crexendo. These are the company’s own figures put through the tests he described. What he looks at, and why →
Joel Greenblatt 0/1
| Measure | CXDO | Checked against | |
|---|---|---|---|
| Return on capital employed | -3.7% | median 10.1% | ✗ |
Passes 0 of 1. To be clear: Joel Greenblatt has never said anything about Crexendo. These are the company’s own figures put through the tests he described. What he looks at, and why →
Peter Lynch 1/2
| Measure | CXDO | Checked against | |
|---|---|---|---|
| Debt to equity | 0.02x | median 0.79x | ✓ |
| Net margin | -0.7% | median 10.2% | ✗ |
Passes 1 of 2. To be clear: Peter Lynch has never said anything about Crexendo. These are the company’s own figures put through the tests he described. What he looks at, and why →
Last usable year: 2023-12-31 — 32 months ago. Nothing filed since gives the figures a payout ratio needs. For a company that once paid, that usually means it stopped.
| Basis | Payout | Why |
|---|---|---|
| GAAP earnings | negative | whyLost $0.0100 per share — no earnings to pay from. |
| Operating cash flow | 3.7% | whyBefore capital spending. |
| Free cash flow | 3.8% | whyAfter maintaining the business. |
All bases agree, within a point.
Coverage rating 73 / 100 — Adequate. ? Peer standing 48/50Direction 15/30Stability 10/20
The arithmetic
- GAAP earnings — dividends declared per share $0.0050 ÷ diluted EPS $-0.0100
- Operating cash flow — dividends paid $130k ÷ operating cash flow $3.50m
- Free cash flow — dividends paid $130k ÷ (operating cash flow $3.50m − capex $92k)
Where the figures came from
- 10-K filed 2025-03-04 · accession 0001654954-25-002287
- 10-K filed 2026-03-03 · accession
0001654954-26-001848 - 10-K filed 2024-03-05 · accession
0001654954-24-002655
All public at sec.gov — you should not have to take our word for it.
Caveats on this company
- DPS derived from dividends paid ($0.01); no per-share tag filed
Computed straight from SEC XBRL. A number that looks wrong to you is more useful to us than agreement — tell us.
What the free cash flow payout ratio measures, and where every company here sits on it.
Also on: rated adequate · when it files.
When this changes
Every figure above is recomputed whenever Crexendo files. The monthly letter carries what filed, what moved, and one finding computed across every company here.